肺分子分级预后评估(Lung-molGPA)预测接受立体定向放疗的非小细胞肺癌脑转移患者生存的外部验证
本研究对241例接受立体定向放疗的非小细胞肺癌腺癌脑转移患者进行回顾性分析,首次外部验证更新版Lung-molGPA模型。整体中位生存期为15个月,预测与观察中位生存期在除最有利预后组外的各组相似,C统计量和Brier评分显示预测准确。结论认为该模型可准确预测欧洲人群生存,但对小样本的最有利预后组高估生存。
要点
- Lung-molGPA在241例立体定向放疗的非小细胞肺癌脑转移患者中外部验证,整体中位生存期15个月。
- 除最有利预后组外,预测与观察中位生存期在原始队列和验证队列间相似。
- C统计量和Brier评分显示模型预测准确,但最有利预后组生存被高估。
核心结论
- Lung-molGPA在我们的欧洲人群中准确预测了生存,除了对小样本的最有利预后组高估了生存。
- 该预后模型已获外部验证,因此可用于非小细胞肺癌腺癌脑转移患者的咨询。
研究设计与样本
- 回顾性纳入接受立体定向放疗的非小细胞肺癌腺癌脑转移患者,共241例。
- 基于年龄、卡氏功能状态评分、脑转移数目、颅外转移、EGFR/ALK状态和PD-L1表达六项预后因素计算GPA评分。
- 采用Kaplan-Meier分析评估生存概率,Cox比例风险模型进行单因素和多因素分析评估各预后因素对生存的影响。
- 采用C统计量评估区分度,Brier检验评估校准度。
主要发现
- 队列(n=241)分为四个预后组。
- 整体中位生存期为15个月。
- 除最有利预后组外,原始队列和验证队列的预测与观察中位生存期相似。
- C统计量和Brier评分 adequate,Lung-molGPA提供了准确的生存预测。
关键数值与推荐
- GPA评分基于六项预后因素:年龄、卡氏功能状态评分、脑转移数目、颅外转移、EGFR/ALK状态和PD-L1表达。
- 整体中位生存期为15个月。
临床怎么用
- 该预后模型已获外部验证,可用于非小细胞肺癌腺癌脑转移患者的咨询。
局限性
- 原文报告对最有利预后组高估了生存,该组样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the era of personalized medicine, individualized prognostic models with tumor characteristics are needed to inform patients about survival. Before clinical use, external validation of such models by an independent group is needed. An updated version of the graded prognostic assessment (GPA) estimates survival in patients with brain metastases (BMs) of non-small cell lung cancer (NSCLC). This is the first external validation of the updated Lung-molGPA in patients treated with stereotactic radiotherapy (SRT) for one or more BMs. MATERIALS AND METHODS: Patients treated with SRT for BMs from NSCLC adenocarcinoma were retrospectively included. GPA score was calculated for each patient based on six prognostic factors including age, Karnofsky Performance Status, number of BMs, extracranial metastases, EGFR/ALK status, and PD-L1 expression. Kaplan-Meier analysis evaluated survival probability. Impact of individual prognostic factors on survival was assessed by univariate and multivariate analyses using the Cox proportional hazard model. Predictive performance was evaluated using discrimination (C-statistic) and calibration (Brier test). RESULTS: The cohort (n = 241) was divided into four prognostic groups. Overall median survival was 15 months. Predicted and observed median survival were similar between the original and validation cohorts, apart from the most favorable prognostic group. With adequate C-statistics and Brier scores, the Lung-molGPA provided accurate survival predictions. CONCLUSION: The Lung-molGPA accurately predicted survival in our European population, except for an overestimation of survival in the small most favorable prognostic group. This prognostic model was externally validated and is therefore useful for counseling of patients with BMs of NSCLC adenocarcinoma.
引用
- Crouzen JA, Mast ME, Hakstege M, et al. External validation of the lung-molGPA to predict survival in patients treated with stereotactic radiotherapy for brain metastases of non-small cell lung cancer. Radiother Oncol. 2024. PMID: 38925263. doi:10.1016/j.radonc.2024.110405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。